Cerity Partners LLC Makes New Investment in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Cerity Partners LLC purchased a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 33,384 shares of the company's stock, valued at approximately $834,000.

Other large investors have also recently added to or reduced their stakes in the company. Rubric Capital Management LP boosted its position in Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company's stock worth $45,165,000 after purchasing an additional 223,094 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Kiniksa Pharmaceuticals by 31.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company's stock worth $12,398,000 after buying an additional 157,741 shares during the period. Rice Hall James & Associates LLC raised its holdings in Kiniksa Pharmaceuticals by 8.2% in the 3rd quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company's stock valued at $16,234,000 after acquiring an additional 49,000 shares during the period. Millennium Management LLC lifted its position in Kiniksa Pharmaceuticals by 159.8% during the second quarter. Millennium Management LLC now owns 621,948 shares of the company's stock worth $11,612,000 after acquiring an additional 382,539 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Kiniksa Pharmaceuticals by 40.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 324,064 shares of the company's stock worth $8,098,000 after acquiring an additional 92,985 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on KNSA shares. JPMorgan Chase & Co. lifted their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Evercore ISI lifted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. Finally, Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a "buy" rating and a $40.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $36.60.

Insider Activity

In other news, COO Eben Tessari sold 17,500 shares of the company's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.99, for a total transaction of $437,325.00. Following the completion of the transaction, the chief operating officer now directly owns 116,975 shares in the company, valued at approximately $2,923,205.25. This represents a 13.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of the firm's stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total value of $192,385.05. Following the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at approximately $492,449.10. This trade represents a 28.09 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 44,592 shares of company stock worth $1,110,364. Insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Stock Up 2.5 %

Shares of NASDAQ:KNSA traded up $0.53 during trading on Friday, reaching $21.51. 264,488 shares of the company traded hands, compared to its average volume of 400,810. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15. The firm has a market capitalization of $1.55 billion, a PE ratio of -149.86 and a beta of 0.27. The company's 50 day moving average is $23.71 and its two-hundred day moving average is $22.97.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.17). The firm had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company's quarterly revenue was up 67.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.20) earnings per share. As a group, research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.